Samir F Saba

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9416899/publications.pdf Version: 2024-02-01



SAMID F SARA

#	Article	IF	CITATIONS
1	Novel Speckle-Tracking Radial Strain From Routine Black-and-White Echocardiographic Images to Quantify Dyssynchrony and Predict Response to Cardiac Resynchronization Therapy. Circulation, 2006, 113, 960-968.	1.6	761
2	Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics, 2018, 50, 1225-1233.	21.4	552
3	Continued Rise in Rates of Cardiovascular Implantable Electronic Device Infections in the United States: Temporal Trends and Causative Insights. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 414-419.	1.2	350
4	Rising Rates of Cardiac Rhythm Management Device Infections in the United States: 1996 through 2003. Journal of the American College of Cardiology, 2006, 48, 590-591.	2.8	332
5	Echocardiography-Guided Left Ventricular Lead Placement for Cardiac Resynchronization Therapy. Circulation: Heart Failure, 2013, 6, 427-434.	3.9	330
6	Combined Longitudinal and Radial Dyssynchrony Predicts Ventricular Response After Resynchronization Therapy. Journal of the American College of Cardiology, 2007, 50, 1476-1483.	2.8	237
7	Dyssynchrony by speckle-tracking echocardiography and response to cardiac resynchronization therapy: results of the Speckle Tracking and Resynchronization (STAR) study. European Heart Journal, 2010, 31, 1690-1700.	2.2	236
8	Scar burden by myocardial perfusion imaging predicts echocardiographic response to cardiac resynchronization therapy in ischemic cardiomyopathy. American Heart Journal, 2007, 153, 105-112.	2.7	228
9	Relationship of Echocardiographic Dyssynchrony to Long-Term Survival After Cardiac Resynchronization Therapy. Circulation, 2010, 122, 1910-1918.	1.6	170
10	Impact of scar burden by single-photon emission computed tomography myocardial perfusion imaging on patient outcomes following cardiac resynchronization therapy. European Heart Journal, 2011, 32, 93-103.	2.2	158
11	Identification of Typical Left Bundle Branch Block Contraction by Strain Echocardiography Is Additive to Electrocardiography in Prediction of Long-Term Outcome After Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2015, 66, 631-641.	2.8	132
12	Machine learning-based prediction of acute coronary syndrome using only the pre-hospital 12-lead electrocardiogram. Nature Communications, 2020, 11, 3966.	12.8	102
13	Usefulness of Baseline Electrocardiographic QRS Complex Pattern to Predict Response to Cardiac Resynchronization. American Journal of Cardiology, 2009, 103, 238-242.	1.6	96
14	Predictors of Complications of Endovascular Chronic Lead Extractions from Pacemakers and Defibrillators: A Singleâ€Operator Experience. Journal of Cardiovascular Electrophysiology, 2009, 20, 171-175.	1.7	92
15	A Prospective Pilot Study to Evaluate the Relationship Between Acute Change in Left Ventricular Synchrony After Cardiac Resynchronization Therapy and Patient Outcome Using a Single-Injection Gated SPECT Protocol. Circulation: Cardiovascular Imaging, 2011, 4, 532-539.	2.6	92
16	The relationship of QRS morphology and mechanical dyssynchrony to long-term outcome following cardiac resynchronization therapy. European Heart Journal, 2012, 33, 2680-2691.	2.2	87
17	Health and Economic Outcomes Associated with Use of an Antimicrobial Envelope as a Standard of Care for Cardiac Implantable Electronic Device Implantation. Journal of Cardiovascular Electrophysiology, 2015, 26, 783-789.	1.7	74
18	Efficient Compression of QRS Complexes Using Hermite Expansion. IEEE Transactions on Signal Processing, 2012, 60, 947-955.	5.3	71

#	Article	IF	CITATIONS
19	Utilization of implantable cardioverter-defibrillators in survivors of cardiac arrest in the United States from 1996 to 2001. Journal of the American College of Cardiology, 2004, 44, 855-858.	2.8	66
20	Independent multicenter study of Riata and Riata ST implantable cardioverter-defibrillator leads. Heart Rhythm, 2013, 10, 361-365.	0.7	65
21	Renal insufficiency predicts the time to first appropriate defibrillator shock. American Heart Journal, 2006, 151, 852-856.	2.7	59
22	Location of Acute Myocardial Infarction and Associated Arrhythmias and Outcome. Clinical Cardiology, 2009, 32, 274-277.	1.8	58
23	Class I recall of defibrillator leads: A comparison of the Sprint Fidelis and Riata families. Heart Rhythm, 2012, 9, 1251-1255.	0.7	54
24	Response to Cardiac Resynchronization Therapy in Patients with Heart Failure and Renal Insufficiency. PACE - Pacing and Clinical Electrophysiology, 2010, 33, 850-859.	1.2	50
25	Utility of the Wearable Cardioverter-Defibrillator in Patients WithÂNewly Diagnosed Cardiomyopathy. Journal of the American College of Cardiology, 2015, 66, 2607-2613.	2.8	50
26	Effect of Echocardiography-Guided Left Ventricular Lead Placement for Cardiac Resynchronization Therapy on Mortality and Risk of Defibrillator Therapy for Ventricular Arrhythmias in Heart Failure Patients (from the Speckle Tracking Assisted Resynchronization Therapy for Electrode Region) Tj ETQq0 0 0 rgBT	- /ðverlock	10 ⁵ Tf 50 452
27	Multicenter experience with extraction of the Riata/Riata ST ICD lead. Heart Rhythm, 2014, 11, 1613-1618.	0.7	45
28	Prediction of Response to Cardiac Resynchronization Therapy by Speckle Tracking Echocardiography Using Different Software Approaches. Journal of the American Society of Echocardiography, 2009, 22, 677-684.	2.8	43
29	Fluoroscopic Screening of Asymptomatic Patients Implanted With the Recalled Riata Lead Family. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 809-814.	4.8	42
30	Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation. Stroke, 2017, 48, 159-166.	2.0	42
31	Usefulness of Echocardiographically Guided Left Ventricular Lead Placement for Cardiac Resynchronization Therapy in Patients With Intermediate QRS Width and Non–Left Bundle Branch Block Morphology. American Journal of Cardiology, 2014, 113, 107-116.	1.6	40
32	Additive Prognostic Value of Echocardiographic Global Longitudinal and Global Circumferential Strain to Electrocardiographic Criteria in Patients With Heart Failure Undergoing Cardiac Resynchronization Therapy. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	40
33	New-onset left bundle branch block–associated idiopathic nonischemic cardiomyopathy and left ventricular ejection fraction response to guideline-directed therapies: The NEOLITH study. Heart Rhythm, 2016, 13, 933-942.	0.7	39
34	Wearable Cardioverter-Defibrillator Therapy for the Prevention of SuddenÂCardiac Death. JACC: Clinical Electrophysiology, 2019, 5, 152-161.	3.2	39
35	Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin in Patients With Chronic Kidney Disease and Atrial Fibrillation. American Journal of Cardiology, 2020, 125, 210-214.	1.6	39
36	Mechanical Dyssynchrony after Cardiac Resynchronization Therapy for Severely Symptomatic Heart Failure Is Associated with Risk for Ventricular Arrhythmias. Journal of the American Society of Echocardiography, 2014, 27, 872-879.	2.8	38

#	Article	IF	CITATIONS
37	Women and minorities are less likely to receive an implantable cardioverter defibrillator for primary prevention of sudden cardiac death. Europace, 2012, 14, 341-344.	1.7	37
38	Effect of body mass index on survival after sudden cardiac arrest. Clinical Cardiology, 2018, 41, 46-50.	1.8	37
39	Efficacy of Cryoballoon Pulmonary Vein Isolation in Patients With Persistent Atrial Fibrillation. Journal of Cardiovascular Electrophysiology, 2016, 27, 423-427.	1.7	36
40	Incidence and Predictors of Complications During Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation. Journal of the American Heart Association, 2016, 5, .	3.7	36
41	Effect of Endâ€Stage Renal Failure and Hemodialysis on Mortality Rates in Implantable Cardioverterâ€Defibrillator Recipients. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1091-1095.	1.2	34
42	Longitudinal Follow-Up of Implantable Cardioverter DefibrillatorÂLeads. American Journal of Cardiology, 2014, 113, 103-106.	1.6	33
43	Effect of Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers on Appropriate Implantable Cardiac Defibrillator Shock in Patients With Severe Systolic Heart Failure (from the GRADE) Tj ETQq1 1 0.78431	.4 rg₿∂T /O¹	verl os k 10 T ^e
44	Effectiveness of Implantable Defibrillators in Octogenarians and Nonagenarians for Primary Prevention of Sudden Cardiac Death. American Journal of Cardiology, 2011, 108, 718-722.	1.6	32
45	The Association of Left Ventricular Lead Position Related to Regional Scar by Speckle-Tracking Echocardiography with Clinical Outcomes in Patients Receiving Cardiac Resynchronization Therapy. Journal of the American Society of Echocardiography, 2014, 27, 648-656.	2.8	32
46	Soft Miniaturized Actuation and Sensing Units for Dynamic Force Control of Cardiac Ablation Catheters. Soft Robotics, 2021, 8, 59-70.	8.0	32
47	Right atrial pacing and the risk of postimplant atrial fibrillation in cardiac resynchronization therapy recipients. American Heart Journal, 2008, 155, 94-99.	2.7	31
48	Biventricular pacing reduces ventricular arrhythmic burden and defibrillator therapies in patients with heart failure. Clinical Cardiology, 2006, 29, 74-77.	1.8	30
49	Comparative long-term outcomes after cardiac resynchronization therapy in right ventricular paced patients versus native wide left bundle branch block patients. Heart Rhythm, 2016, 13, 511-518.	0.7	29
50	Gender differences in management and clinical outcomes of atrial fibrillation patients. Journal of Cardiology, 2017, 69, 195-200.	1.9	29
51	Outcomes of Sprint Fidelis and Riata lead extraction: Data from 2 high-volume centers. Heart Rhythm, 2015, 12, 1216-1220.	0.7	28
52	Extracting Versus Abandoning Sterile Pacemaker and Defibrillator Leads. American Journal of Cardiology, 2015, 115, 1107-1110.	1.6	28
53	Catheter ablation of ventricular tachycardia: Lessons learned from past clinical trials and implications for future clinical trials. Heart Rhythm, 2016, 13, 1748-1754.	0.7	28
54	Trends in hospitalization for congestive heart failure, 1996–2009. Clinical Cardiology, 2017, 40, 109-119.	1.8	28

#	Article	IF	CITATIONS
55	Newâ€onset left bundle branch blockâ€associated idiopathic nonischemic cardiomyopathy and time from diagnosis to cardiac resynchronization therapy: The NEOLITH II study. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 143-154.	1.2	28
56	Left Ventricular Dilatation Increases the Risk of Ventricular Arrhythmias in Patients With Reduced Systolic Function. Journal of the American Heart Association, 2015, 4, e001566.	3.7	27
57	Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories. JACC: Clinical Electrophysiology, 2021, 7, 649-658.	3.2	26
58	Complications of replacing implantable devices in response to advisories: A single center experience. International Journal of Cardiology, 2009, 134, 42-46.	1.7	25
59	Mechanical Dyssynchrony by Tissue Doppler Cross-Correlation is Associated with Risk for Complex Ventricular Arrhythmias after Cardiac Resynchronization Therapy. Journal of the American Society of Echocardiography, 2015, 28, 1474-1481.	2.8	25
60	Implantable cardioverter defibrillators confer survival benefit in patients with renal insufficiency but not in dialysis-dependent patients. Journal of Interventional Cardiac Electrophysiology, 2010, 28, 117-123.	1.3	24
61	Outpatient Management of Heart Failure in the United States, 2006–2008. Texas Heart Institute Journal, 2014, 41, 253-261.	0.3	22
62	Echocardiography-guided left ventricular lead placement for cardiac resynchronization therapy in ischemic vs nonischemic cardiomyopathy patients. Heart Rhythm, 2014, 11, 614-619.	0.7	22
63	Recent Trends in Utilization of Implantable Cardioverterâ€Defibrillators in Survivors of Cardiac Arrest in the United States. PACE - Pacing and Clinical Electrophysiology, 2009, 32, 1444-1449.	1.2	21
64	Battery longevity from cardiac resynchronization therapy defibrillators: differences between manufacturers and discrepancies with published product performance reports. Europace, 2017, 19, euw044.	1.7	21
65	Prevalence of Atrial Fibrillation and Thromboembolic Risk in Wild-Type Transthyretin Amyloid Cardiomyopathy. Circulation, 2021, 143, 1335-1337.	1.6	21
66	Comparative effectiveness of antiarrhythmic drugs for rhythm control of atrial fibrillation. Journal of Cardiology, 2016, 67, 471-476.	1.9	20
67	Implantable Defibrillator Therapy in Cardiac Arrest Survivors With a Reversible Cause. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e005940.	4.8	20
68	In Search of an Optimal Subset of ECG Features to Augment the Diagnosis of Acute Coronary Syndrome at the Emergency Department. Journal of the American Heart Association, 2021, 10, e017871.	3.7	20
69	Combined Atrial and Ventricular Antitachycardia Pacing as a Novel Method of Rhythm Discrimination. Circulation, 2010, 121, 487-497.	1.6	19
70	Failure-free survival of the Durata defibrillator lead. Europace, 2013, 15, 1002-1006.	1.7	19
71	Dual-Dye Optical Mapping after Myocardial Infarction: Does the Site of Ventricular Stimulation Alter the Properties of Electrical Propagation?. Journal of Cardiovascular Electrophysiology, 2008, 19, 197-202.	1.7	18
72	Relationship between left ventricular dyssynchrony and scar burden in the genesis of ventricular tachyarrhythmia. Journal of Nuclear Cardiology, 2018, 25, 555-569.	2.1	18

#	Article	IF	CITATIONS
73	Measures of Left Ventricular Dyssynchrony and the Correlation to Clinical and Echocardiographic Response After Cardiac Resynchronization Therapy. American Journal of Cardiology, 2008, 102, 598-601.	1.6	17
74	Lead related complications in quadripolar versus bipolar left ventricular leads. Indian Pacing and Electrophysiology Journal, 2017, 17, 3-7.	0.6	17
75	Geographic Variation in the Use of Oral Anticoagulation Therapy in Stroke Prevention in Atrial Fibrillation. Stroke, 2017, 48, 2289-2291.	2.0	17
76	Cardiac resynchronization therapy using pacemakers vs defibrillators in patients with nonischemic cardiomyopathy: The United States experience from 2007 to 2014. Heart Rhythm, 2019, 16, 1065-1071.	0.7	17
77	Effect of Right Ventricular Versus Biventricular Pacing on Electrical Remodeling in the Normal Heart. Circulation: Arrhythmia and Electrophysiology, 2010, 3, 79-87.	4.8	16
78	Effect of concordance between sites of left ventricular pacing and dyssynchrony on acute electrocardiographic and echocardiographic parameters in patients with heart failure undergoing cardiac resynchronization therapy. Clinical Cardiology, 2006, 29, 498-502.	1.8	15
79	Prevention of adverse electrical and mechanical remodeling with biventricular pacing in a rabbit model of myocardial infarction. Heart Rhythm, 2008, 5, 124-130.	0.7	15
80	Clinical outcomes in cardiac resynchronization therapy-defibrillator recipients 80 years of age and older. Europace, 2016, 18, 420-427.	1.7	15
81	Causes and Predictors of 30-Day Readmissions in Atrial Fibrillation (from the Nationwide) Tj ETQq1 1 0.784314	⊦rgBT /Ovei 1.6	rlock 10 Tf 5၀
82	Nonâ€vitamin K oral anticoagulants versus warfarin for left atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1183-1190.	1.2	15
83	Mechanical dyssynchrony is additive to ECG criteria and independently associated with reverse remodelling and clinical response to cardiac resynchronisation therapy in patients with advanced heart failure. Open Heart, 2015, 2, e000246.	2.3	14
84	Predictors and outcomes of lead extraction requiring a bailout femoral approach: Data from 2 high-volume centers. Heart Rhythm, 2017, 14, 548-552.	0.7	14
85	Interaction of Left Ventricular Remodeling and Regional Dyssynchrony on Long-Term Prognosis after Cardiac Resynchronization Therapy. Journal of the American Society of Echocardiography, 2017, 30, 244-250.	2.8	14
86	Implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a meta-analysis of randomized controlled trials. Cardiovascular Diagnosis and Therapy, 2017, 7, 397-404.	1.7	14
87	Cardiovascular Disease Risk–Based Statin Utilization and Associated Outcomes in a Primary Prevention Cohort: Insights From a Large Health Care Network. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007485.	2.2	14
88	Gene-Targeted Mice with the Human Troponin T R141W Mutation Develop Dilated Cardiomyopathy with Calcium Desensitization. PLoS ONE, 2016, 11, e0167681.	2.5	14
89	Cardiac implantable electronic device lead extraction in patients with underlying infection using open thoracotomy or percutaneous techniques. Cardiology Journal, 2015, 22, 68-74.	1.2	14
90	Failure Rates of Single- Versus Dual-Coil Nonrecalled Sprint Quattro Defibrillator Leads. American Journal of Cardiology, 2015, 115, 202-205.	1.6	13

#	Article	IF	CITATIONS
91	Influence of patients' age at implantation on mortality and defibrillator shocks. Europace, 2017, 19, euw085.	1.7	13
92	Infection and readmission rate of cardiac implantable electronic device insertions: An observational single center study. American Journal of Infection Control, 2016, 44, 278-282.	2.3	13
93	Persistent sex disparities in implantable cardioverterâ€defibrillator therapy. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1150-1157.	1.2	13
94	Longitudinal Follow-Up of Externalized Riata Leads. American Journal of Cardiology, 2013, 112, 1616-1618.	1.6	12
95	Clinical Characteristics and Outcomes of Older Cardiac Resynchronization Therapy Recipients Using a Pacemaker versus a Defibrillator. Journal of Cardiovascular Electrophysiology, 2016, 27, 730-734.	1.7	12
96	Leadless pacemakers: A new era in cardiac pacing. Journal of Cardiology, 2016, 67, 1-5.	1.9	12
97	Use of Correlation Waveform Analysis in Discrimination Between Anterograde and Retrograde Atrial Electrograms During Ventricular Tachycardia. Journal of Cardiovascular Electrophysiology, 2001, 12, 145-149.	1.7	11
98	Baseline Scintigraphic Abnormalities by Myocardial Perfusion Imaging Predict Echocardiographic Response to Cardiac Resynchronization Therapy in Nonischemic Cardiomyopathy. Clinical Cardiology, 2008, 31, 217-224.	1.8	11
99	Extraction of defibrillator leads recalled for cable externalization and failure. Journal of Interventional Cardiac Electrophysiology, 2013, 36, 273-278.	1.3	11
100	Prophylactic Lead Extraction at Implantable Cardioverter-Defibrillator Generator Change. Circulation: Arrhythmia and Electrophysiology, 2014, 7, 330-336.	4.8	11
101	Oral anticoagulation and left atrial thrombi resolution in nonrheumatic atrial fibrillation or flutter: A systematic review and metaâ€analysis. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 767-774.	1.2	11
102	Cluster Randomized Trial Examining the Impact of Automated Best Practice Alert on Rates of Implantable Defibrillator Therapy. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005024.	2.2	11
103	Impact of Change in 2010 American Heart Association Cardiopulmonary Resuscitation Guidelines on Survival After Out-of-Hospital Cardiac Arrest in the United States. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007843.	4.8	11
104	Predictors of Cardiac Arrest Occurring in the Context of Acute Myocardial Infarction. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 1262-1266.	1.2	10
105	Patient Outcomes According to Adherence to Treatment Guidelines for Rhythm Control of Atrial Fibrillation. Journal of the American Heart Association, 2015, 4, .	3.7	10
106	Increased left atrial size is associated with higher atrial fibrillation recurrence in patients treated with antiarrhythmic medications. Clinical Cardiology, 2018, 41, 825-829.	1.8	10
107	Cardiac resynchronization therapy pacemakers versus defibrillators in older non-ischemic cardiomyopathy patients. Indian Pacing and Electrophysiology Journal, 2019, 19, 4-6.	0.6	10
108	Characterization of pulmonary vein reconnection post Cryoballoon ablation. Indian Pacing and Electrophysiology Journal, 2019, 19, 129-133.	0.6	10

#	Article	IF	CITATIONS
109	Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008991.	4.8	10
110	Simultaneous Atrial and Ventricular Anti-Tachycardia Pacing as a Novel Method of Rhythm Discrimination. Journal of Cardiovascular Electrophysiology, 2006, 17, 695-701.	1.7	9
111	Cardiac levels of NOS1AP RNA from right ventricular tissue recovered during lead extraction. Heart Rhythm, 2012, 9, 399-404.	0.7	9
112	Trends and Predictors of 30-day Readmission Among Patients Hospitalized with Infective Endocarditis in the United States. Cureus, 2019, 11, e4962.	0.5	9
113	Trends in Hospital Admissions for and Readmissions After Cardiac Implantable Electronic Device Procedures in the United States: An Analysis From 2010 to 2014 Using the National Readmission Database. Mayo Clinic Proceedings, 2019, 94, 588-598.	3.0	9
114	Effectiveness and Safety of Restarting Oral Anticoagulation in Patients with Atrial Fibrillation after an Intracranial Hemorrhage: Analysis of Medicare Part D Claims Data from 2010–2016. American Journal of Cardiovascular Drugs, 2020, 20, 471-479.	2.2	9
115	Maternal focal atrial tachycardia during pregnancy: A systematic review. Journal of Cardiovascular Electrophysiology, 2020, 31, 2982-2997.	1.7	9
116	Circadian Pattern of Ion Channel Gene Expression in Failing Human Hearts. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e009254.	4.8	9
117	Novel ECC features and machine learning to optimize culprit lesion detection in patients with suspected acute coronary syndrome. Journal of Electrocardiology, 2021, 69, 31-37.	0.9	9
118	Mortality risk of long-term amiodarone therapy for atrial fibrillation patients without structural heart disease. Cardiology Journal, 2015, 22, 622-629.	1.2	9
119	Mechanisms of Inappropriate Defibrillator Therapy in a Modern Cohort of Remotely Monitored Patients. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 547-552.	1.2	8
120	Characteristics and Outcomes of Concurrently Diagnosed New Rapid Atrial Fibrillation or Flutter and New Reduced Ejection Fraction. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 1394-1403.	1.2	8
121	Impact of 3D mapping on procedural characteristics and outcomes in cryoballoon pulmonary vein isolation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 71-75.	1.3	8
122	Implantable cardioverterâ€defibrillator therapy in device recipients who survived a cardiac arrest associated with a reversible cause. Journal of Cardiovascular Electrophysiology, 2018, 29, 1413-1417.	1.7	8
123	Amiodarone is associated with adverse outcomes in patients with sustained ventricular arrhythmias upgraded to cardiac resynchronization therapy—defibrillators. Journal of Cardiovascular Electrophysiology, 2019, 30, 348-356.	1.7	8
124	Programmatic Responses to the Coronavirus Pandemic: A Survey of 502 Cardiac Surgeons. Annals of Thoracic Surgery, 2020, 110, 761-763.	1.3	8
125	A Clinical Risk Score to Predict the Time to First Appropriate Device Therapy in Recipients of Implantable Cardioverter Defibrillators. PACE - Pacing and Clinical Electrophysiology, 2007, 30, 385-389.	1.2	7
126	Use of Cardiac Implantable Electronic Devices in Older Adults With Cognitive Impairment. JAMA Internal Medicine, 2014, 174, 1514.	5.1	7

#	Article	IF	CITATIONS
127	Dynamic Abandon/Extract Decisions for Failed Cardiac Leads. Management Science, 2018, 64, 633-651.	4.1	7
128	Impact of Race on Outcome of Patients Undergoing Rhythm Control of Atrial Fibrillation. Journal of Immigrant and Minority Health, 2018, 20, 14-19.	1.6	7
129	Causes and predictors of 30â€day readmission after cardiovascular implantable electronic devices implantation: Insights from Nationwide Readmissions Database. Journal of Cardiovascular Electrophysiology, 2018, 29, 456-462.	1.7	7
130	Comparison of Long-Term Survival Following Sudden Cardiac Arrest in Men Versus Women. American Journal of Cardiology, 2019, 124, 362-366.	1.6	7
131	Myocardial recovery after cardiac resynchronization therapy in left bundle branch blockâ€associated idiopathic nonischemic cardiomyopathy: A NEOLITH II substudy. Annals of Noninvasive Electrocardiology, 2019, 24, e12603.	1.1	7
132	Use Trends and Adverse Reports of SelectSecure 3830 Lead Implantations in the United States. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e008577.	4.8	7
133	Management of systemic fungal infections in the presence of a cardiac implantable electronic device: A systematic review. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 159-166.	1.2	7
134	Wide and Narrow Complex Tachycardias: What Is the Mechanism?. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 1810-1811.	1.2	6
135	New method for real-time discrimination and management of ventricular and supraventricular tachyarrhythmias applicable to patients with dual-chamber cardioverter-defibrillators. American Journal of Cardiology, 2004, 93, 111-114.	1.6	6
136	Biventricular Defibrillator Patients Have Higher Complication Rates after Revision of Recalled Leads. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 665-671.	1.2	6
137	Targeting Left Ventricular Lead Placement to Improve Cardiac Resynchronization Therapy Outcomes. Current Cardiology Reports, 2013, 15, 390.	2.9	6
138	Risk of Stroke and Death in Atrial Fibrillation by Type of Anticoagulation: A Propensity-Matched Analysis. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 1310-1316.	1.2	6
139	Usefulness of the CHA 2 DS 2 -VASc Score to Predict Mortality in Defibrillator Recipients. American Journal of Cardiology, 2017, 120, 83-86.	1.6	6
140	Derivation and validation of a new score to predict longâ€ŧerm survival after sudden cardiac arrest. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1585-1590.	1.2	6
141	A Qualitative Analysis of Patient-Related Factors Associated With Implantable Cardioverter Defibrillator Acceptance. Cardiology and Therapy, 2020, 9, 421-432.	2.6	6
142	Identifying the most important ECG predictors of reduced ejection fraction in patients with suspected acute coronary syndrome. Journal of Electrocardiology, 2020, 61, 81-85.	0.9	6
143	Priority plan for invasive cardiac electrophysiology procedures during the coronavirus disease 2019 (COVIDâ€19) pandemic. Journal of Cardiovascular Electrophysiology, 2020, 31, 1255-1258.	1.7	6
144	Usefulness of Multisite Ventricular Pacing in Nonresponders to Cardiac Resynchronization Therapy. American Journal of Cardiology, 2022, 164, 86-92.	1.6	6

#	Article	IF	CITATIONS
145	Cardiac Autonomic Modulation by Estrogen in Female Mice Undergoing Ambulatory Monitoring and In Vivo Electrophysiologic Testing. Annals of Noninvasive Electrocardiology, 2004, 9, 142-148.	1.1	5
146	To Extract or Retain a Sterile, Nonfunctional Lead. Cardiac Electrophysiology Clinics, 2015, 7, 419-425.	1.7	5
147	Antithrombotic Therapy in Nonvalvular Atrial Fibrillation: Consensus and Challenges. American Journal of the Medical Sciences, 2018, 355, 467-476.	1.1	5
148	Rate and predictors of electrical failure in non-recalled defibrillator leads. Indian Pacing and Electrophysiology Journal, 2019, 19, 100-103.	0.6	5
149	Primary prevention of sudden death with the implantable cardioverter defibrillator: bridging the evidence gap. European Heart Journal, 2020, 41, 3448-3450.	2.2	5
150	Improved Resource Utilization With Similar Efficacy During Early Adoption of Cryoballoon Pulmonary Vein Isolation as Compared to Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. Journal of Atrial Fibrillation, 2015, 7, 1191.	0.5	5
151	Trends in atrial fibrillation hospitalizations in the United States: AÂreport using data from the National Hospital Discharge Survey. Indian Pacing and Electrophysiology Journal, 2018, 18, 6-12.	0.6	4
152	Lower socioeconomic status is associated with increased longâ€ŧerm mortality after sudden cardiac arrest. Clinical Cardiology, 2019, 42, 735-740.	1.8	4
153	Trends and Implications of DF-4 Implantable Cardioverter-Defibrillator Lead Adoption in the United States of America. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007134.	4.8	4
154	Impact of Diabetes Mellitus on Mortality and Hospitalization in Patients With Mild-to-Moderate Cardiomyopathy. JACC: Clinical Electrophysiology, 2020, 6, 552-558.	3.2	4
155	On-device Prior Knowledge Incorporated Learning for Personalized Atrial Fibrillation Detection. Transactions on Embedded Computing Systems, 2021, 20, 1-25.	2.9	4
156	ST Elevation in a Patient With COVID-19 Infection-Associated Fever: A Case of Brugada Pattern. Cureus, 2020, 12, e8722.	0.5	4
157	Impact of an Automated Best Practice Alert on Sex and Race Disparities in Implantable Cardioverterâ€Đefibrillator Therapy. Journal of the American Heart Association, 2022, 11, e023669.	3.7	4
158	Targeting the latest site of left ventricular mechanical activation is associated with improved long-term outcomes for recipients of cardiac resynchronization therapy. Heart Rhythm O2, 2022, 3, 377-384.	1.7	4
159	Sudden Cardiac Death Risk Stratification and Assessment: Primary Prevention Based on Ejection Fraction Criteria. Heart Failure Clinics, 2011, 7, 175-183.	2.1	3
160	A Prospective Randomized Controlled Study of Echocardiographic-Guided Lead Placement for Cardiac Resynchronization Therapy: Results of the Starter Trial. Heart Rhythm, 2012, 9, 1581-1582.	0.7	3
161	123I-mIBG scintigraphy: Yet another risk stratifier for the heart failure toolbox!. Journal of Nuclear Cardiology, 2014, 21, 909-912.	2.1	3
162	Long-Term Outcome of Defibrillator Recipients Included in the Federal Audit Conducted by the Department of Justice. American Journal of Cardiology, 2014, 114, 723-726.	1.6	3

#	Article	IF	CITATIONS
163	Gender Differences in Cardiac Resynchronization Therapy Device Choice and Outcome in Patients ≥75 Years of Age with Heart Failure. American Journal of Cardiology, 2017, 120, 2201-2206.	1.6	3
164	Predictors and implications of early left ventricular ejection fraction improvement in newâ€onset idiopathic nonischemic cardiomyopathy with narrow <scp>QRS</scp> complex: A <scp>NEOLITH</scp> substudy. Annals of Noninvasive Electrocardiology, 2017, 22, .	1.1	3
165	Arterial Stiffness Is Associated With QTc Interval Prolongation in Patients With Heart Failure. Biological Research for Nursing, 2018, 20, 255-263.	1.9	3
166	Change in myocardial function after resuscitated sudden cardiac arrest and its impact on long-term mortality and defibrillator implantation. Indian Pacing and Electrophysiology Journal, 2019, 19, 150-154.	0.6	3
167	Implications of Initial Recorded Rhythm on Cardioverter-Defibrillator Insertion and Subsequent All-Cause Mortality in Sudden Cardiac Arrest Survivors. American Journal of Cardiology, 2019, 124, 709-714.	1.6	3
168	Presentation, Treatment, and Outcome of Survivors of In-Hospital Versus Out-of-Hospital Sudden Cardiac Arrest. American Journal of Cardiology, 2020, 125, 1137-1141.	1.6	3
169	Inverse association of mortality and body mass index in patients with left ventricular systolic dysfunction of both ischemic and <scp>nonâ€ischemic</scp> etiologies. Clinical Cardiology, 2021, 44, 495-500.	1.8	3
170	Cardiac resynchronization therapy using a pacemaker or a defibrillator: Patient selection and evidence to support it. Progress in Cardiovascular Diseases, 2021, 66, 46-52.	3.1	3
171	Ventricular pacing and myocardial function in patient with congenital heart block. Journal of Cardiovascular Electrophysiology, 2021, 32, 2684-2689.	1.7	3
172	Im Not Sure We Had A Choice?: Decision Quality and The Use of Cardiac Implantable Electronic Devices In Older Adults With Cognitive Impairment. Cardiology and Cardiovascular Medicine, 2018, 02, 10-26.	0.2	3
173	Feasibility of a Randomized Clinical Trial of Cardiac Resynchronization Therapy With or Without an Implantable Defibrillator in Older Patients. Circulation: Arrhythmia and Electrophysiology, 2022, 15, 101161CIRCEP121010795.	4.8	3
174	Time Shift of Marker Legend in Stored Intracardiac Events in Three Patients with the Vitality 2 EL DR (Model T167) and Prizm 2DR (Model 1861) Dualâ€Chamber Defibrillators. Journal of Cardiovascular Electrophysiology, 2009, 20, 564-567.	1.7	2
175	Pacing Maneuver in the Diagnosis of the Mechanism of Supraventricular Tachycardia. PACE - Pacing and Clinical Electrophysiology, 2011, 34, e90-3.	1.2	2
176	Influence of QRS duration on outcome of death or appropriate defibrillator therapy by strategy of left ventricular lead placement in cardiac resynchronization therapy recipients. Journal of Interventional Cardiac Electrophysiology, 2014, 41, 211-215.	1.3	2
177	X Marks the Spot: Duchenne's Cardiomyopathy. American Journal of Medicine, 2014, 127, e13-e14.	1.5	2
178	Left Atrial Appendage Closure: Killing 2 Birds With 1 Stone?. Journal of the American Heart Association, 2015, 4, .	3.7	2
179	The Truth Is in the Details. Circulation, 2018, 137, 34-37.	1.6	2
180	Cardiac implantable electronic device malfunction after deceleration injury without obvious chest trauma. HeartRhythm Case Reports, 2019, 5, 285-287.	0.4	2

#	Article	IF	CITATIONS
181	Sexâ€specific clinical outcomes after cardiac resynchronization therapy in left bundle branch blockâ€ssociated idiopathic nonischemic cardiomyopathy: A NEOLITH II substudy. Annals of Noninvasive Electrocardiology, 2019, 24, e12641.	1.1	2
182	Documentation of shared decision making around primary prevention defibrillator implantations. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 100-109.	1.2	2
183	Elective implantable cardioverter-defibrillator removal with extraction of leads following catheter ablation of idiopathic ventricular fibrillation and long-term surveillance. HeartRhythm Case Reports, 2020, 6, 464-468.	0.4	2
184	Outcomes of Blacks Versus Whites with Cardiomyopathy. American Journal of Cardiology, 2021, 148, 151-156.	1.6	2
185	Comparison of Circadian Variation for In-Hospital Versus Out-of-Hospital Sudden Cardiac Arrest Survivors. American Journal of Cardiology, 2021, 160, 1-7.	1.6	2
186	Death during acute myocardial infarction: Dodging the first bullet. Heart Rhythm, 2011, 8, 1467-1468.	0.7	1
187	A novel manoeuvre for discerning supraventricular tachycardia mechanism. Europace, 2011, 13, 562-565.	1.7	1
188	Remote device monitoring improves patient outcomes: The definitive evidence may still be remote. Heart Rhythm, 2016, 13, 2287-2288.	0.7	1
189	Don't Just Do Something, Stand There?. Circulation: Arrhythmia and Electrophysiology, 2016, 9, .	4.8	1
190	The Wearable Cardioverter-Defibrillation. JACC: Clinical Electrophysiology, 2018, 4, 240-242.	3.2	1
191	Effectiveness of high rate and delayed detection ICD programming by race: A MADITâ€RIT substudy. Journal of Cardiovascular Electrophysiology, 2018, 29, 1418-1424.	1.7	1
192	Oral anticoagulants for left atrial thrombus resolution in nonvalvular atrial fibrillation or flutter: Building the pyramid of evidence for off″abel drug use. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1601-1602.	1.2	1
193	Improvement in ejection fraction after cryoballoon pulmonary vein isolation for atrial fibrillation in individuals with systolic dysfunction. Journal of Interventional Cardiac Electrophysiology, 2019, 54, 225-229.	1.3	1
194	Left bundle branch block without a typical contraction pattern is associated with increased risk of ventricular arrhythmias in cardiac resynchronization therapy patients. International Journal of Cardiovascular Imaging, 2021, 37, 1843-1851.	1.5	1
195	Cardiac Magnetic Resonance Imaging in Nonischemic Cardiomyopathy. Circulation, 2021, 143, 1374-1376.	1.6	1
196	Frailty as a Predictor of Device Choice and Mortality in Older Cardiac Resynchronization Therapy Recipients. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e010185.	4.8	1
197	Predictors of Hospital Admissions for Ventricular Arrhythmia or Cardiac Arrest in Patients With Cardiomyopathy. American Journal of Cardiology, 2022, 171, 127-131.	1.6	1
198	Multisite Left Ventricular Pacing in Cardiac Resynchronization Therapy. Cardiac Electrophysiology Clinics, 2022, 14, 253-261.	1.7	1

#	Article	IF	CITATIONS
199	Rhythm Classification by Correlation-Waveform Morphology Analysis of Atrial and Ventricular Electrogram Signals. PACE - Pacing and Clinical Electrophysiology, 2005, 28, S54-S56.	1.2	0
200	Letters to the edidor. Clinical Cardiology, 2006, 29, 474-475.	1.8	0
201	Recovery in ERG gene expression with biventricular pacing in a rabbit model of myocardial infarction. Research Reports in Clinical Cardiology, 2013, , 61.	0.2	0
202	Â. Journal of Cardiovascular Electrophysiology, 2015, 26, E13.	1.7	0
203	Response. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 907-907.	1.2	0
204	The impact of a strategy of image-guided left ventricular lead placement during cardiac resynchronization therapy on health care utilization. International Journal of Cardiology, 2015, 187, 311-312.	1.7	0
205	Management of a previously unreported implantable cardioverter-defibrillator lead complication. Europace, 2016, 18, 671-671.	1.7	0
206	Implications of Neurological Status on Defibrillator Therapy and Long-Term Mortality of Sudden Cardiac Arrest Survivors. JACC: Clinical Electrophysiology, 2019, 5, 843-850.	3.2	0
207	Severe chronic kidney disease is associated with poor survival after initial CRTâ€defibrillator tachyarrhythmia therapy. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 78-86.	1.2	Ο
208	Choice and Utility of Pacing Maneuver in Establishing the Mechanism of Supraventricular Tachycardia: A Single Center Experience. Cardiology Research, 2012, 3, 28-33.	1.1	0
209	Atrial Resynchronization Therapy: An Emerging Potential to Advance Physiologic Pacing?. Heart Rhythm, 2021, , .	0.7	О